Basic study of tageting therapy using anti-HER2 anti-body for ovarian cancer

抗HER2抗体靶向治疗卵巢癌的基础研究

• 批准号: 11671633
• 负责人: NAKAJIMA Hisayoshi
• 金额: $ 1.02万
• 依托单位: Nagasaki University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11671633/
• 关键词: ovarian cancer; HER2; tergeting therapy; paclitaxel; SK-OV3; nude mouse; EGF; 抗HER2抗体; target療法

The aim of the study was to investigate the effects of the anti-HER2 antibody on the growth of the SK-OV3 human epitherial ovarian cancers in nude mice. Xenografts were initiated by subcutaneous injection of 1 X 10' SK-OV3 cells into the several nude mice. When the tumors measured about 20mm^3, the mice were divided into experimental groups of S to 10 animals each and the therapy was initiated. Each experiments was done as follows. In experiment the mice with SK-OV3 tumors were divided into 5 groups that received the following treatments as intraperitoneal injections : group 1 was the control group and received saline solution, group 2 received only RhuMahHER2 ; group 3 received only Paclitaxel ; group 4 received only Doxorubicin ; group 5 received RhuMabHER2 and Paclitaxel. Tumors were measured periodicaly and tumor volume was calculated according to the 3 dimentional diameters. The volumes of the SK-OV3 ovarian cancers in the groups that received RhuMabHER2, Doxorubicin and Paclitaxel were slightly, reduced to compared with the control group respectively (not significantly). In the group that received Paclitaxel plus RhuMabHER2 was same reduced to compared with the control group as well as the others. The growth inhibition rate of the tumor, expressed positive immunoreactivity of the HER2 receptor was relatively increased than that of negative tumor, but not significantly. The effects of the anti-HER2 antibody on the growth of the SK-OV3 human epitherial ovarian cancers in nude mice was not clear in this study, further examination was needed.

本研究旨在探讨抗HER2抗体对SK-OV3人卵巢上皮癌裸鼠移植瘤生长的影响。裸鼠皮下注射1×10‘SK-OV3细胞开始异种移植。当肿瘤直径约为20mm2时，将小鼠分为S组和实验组，每组10只，开始治疗。每个实验如下所示。实验中，将SK-OV3荷瘤小鼠分为5组，分别给予生理盐水对照组、大黄组2、紫杉醇组、阿霉素组、大黄+紫杉醇+大黄组。定期测量肿瘤体积，根据三维直径计算肿瘤体积。大黄、阿霉素组和紫杉醇组SK-OV3卵巢癌细胞体积略有缩小，分别与对照组比较差异无统计学意义(P>0.05)。在接受紫杉醇加RhuMabHER2治疗的组中，降幅与对照组及其他组相同。HER2受体阳性表达的肿瘤生长抑制率相对高于阴性肿瘤，但差异无统计学意义。抗HER2抗体对SK-OV3人卵巢上皮癌裸鼠移植瘤生长的影响尚不清楚，有待进一步研究。